We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · January 06, 2022

Radiotherapy + TMZ Is Associated With Improved OS in IDH WT and TERT Promoter–Mutant WHO Grade II/III Gliomas

Radiotherapy & Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Radiotherapy & Oncology
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study
Radiother Oncol 2022 Feb 01;167(xx)1-6, X Qiu, Y Chen, Z Bao, L Chen, T Jiang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading